227 related articles for article (PubMed ID: 25493579)
21. Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in tuberous sclerosis complex consistent with a two-hit model of pathogenesis.
Jóźwiak S; Kwiatkowski D; Kotulska K; Larysz-Brysz M; Lewin-Kowalik J; Grajkowska W; Roszkowski M
J Child Neurol; 2004 Feb; 19(2):102-6. PubMed ID: 15072102
[TBL] [Abstract][Full Text] [Related]
22. Presurgical Administration of mTOR Inhibitors in Patients with Large Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex.
Jiang T; Du J; Raynald ; Wang J; Li C
World Neurosurg; 2017 Nov; 107():1053.e1-1053.e6. PubMed ID: 28866062
[TBL] [Abstract][Full Text] [Related]
23. Pathological Findings of a Subependymal Giant Cell Astrocytoma Following Treatment With Rapamycin.
Cheng S; Hawkins C; Taylor MD; Bartels U
Pediatr Neurol; 2015 Sep; 53(3):238-242.e1. PubMed ID: 26173783
[TBL] [Abstract][Full Text] [Related]
24. Development of hypomelanotic macules is associated with constitutive activated mTORC1 in tuberous sclerosis complex.
Møller LB; Schönewolf-Greulich B; Rosengren T; Larsen LJ; Ostergaard JR; Sommerlund M; Ostenfeldt C; Stausbøl-Grøn B; Linnet KM; Gregersen PA; Jensen UB
Mol Genet Metab; 2017 Apr; 120(4):384-391. PubMed ID: 28336152
[TBL] [Abstract][Full Text] [Related]
25. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis.
Costa V; Aigner S; Vukcevic M; Sauter E; Behr K; Ebeling M; Dunkley T; Friedlein A; Zoffmann S; Meyer CA; Knoflach F; Lugert S; Patsch C; Fjeldskaar F; Chicha-Gaudimier L; Kiialainen A; Piraino P; Bedoucha M; Graf M; Jessberger S; Ghosh A; Bischofberger J; Jagasia R
Cell Rep; 2016 Apr; 15(1):86-95. PubMed ID: 27052171
[TBL] [Abstract][Full Text] [Related]
26. Novel proteins regulated by mTOR in subependymal giant cell astrocytomas of patients with tuberous sclerosis complex and new therapeutic implications.
Tyburczy ME; Kotulska K; Pokarowski P; Mieczkowski J; Kucharska J; Grajkowska W; Roszkowski M; Jozwiak S; Kaminska B
Am J Pathol; 2010 Apr; 176(4):1878-90. PubMed ID: 20133820
[TBL] [Abstract][Full Text] [Related]
27. Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.
Katz JS; Frankel H; Ma T; Zagzag D; Liechty B; Zeev BB; Tzadok M; Devinsky O; Weiner HL; Roth J
Childs Nerv Syst; 2017 Apr; 33(4):601-607. PubMed ID: 28074282
[TBL] [Abstract][Full Text] [Related]
28. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
29. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
[TBL] [Abstract][Full Text] [Related]
30. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
Appalla D; Depalma A; Calderwood S
Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
[TBL] [Abstract][Full Text] [Related]
31. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
32. Developmental origin of subependymal giant cell astrocytoma in tuberous sclerosis complex.
Ess KC; Kamp CA; Tu BP; Gutmann DH
Neurology; 2005 Apr; 64(8):1446-9. PubMed ID: 15851742
[TBL] [Abstract][Full Text] [Related]
33. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
34. Role of mTOR signaling pathway in the pathogenesis of subependymal giant cell astrocytoma - A study of 28 cases.
Kumari K; Sharma MC; Kakkar A; Malgulwar PB; Pathak P; Suri V; Sarkar C; Chandra SP; Faruq M; Gupta RK; Saran RK
Neurol India; 2016; 64(5):988-94. PubMed ID: 27625244
[TBL] [Abstract][Full Text] [Related]
35. The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Palasamudram S; Zak M; Whitney R; McCoy B; Bouffet E; Taylor M; Shroff M; Bartels U
J Neurooncol; 2020 May; 147(3):731-736. PubMed ID: 32285309
[TBL] [Abstract][Full Text] [Related]
36. Applying the Lessons of Tuberous Sclerosis: The 2015 Hower Award Lecture.
Roach ES
Pediatr Neurol; 2016 Oct; 63():6-22. PubMed ID: 27543366
[TBL] [Abstract][Full Text] [Related]
37. Everolimus Treatment for an Early Infantile Subependymal Giant Cell Astrocytoma With Tuberous Sclerosis Complex.
Fukumura S; Watanabe T; Takayama R; Minagawa K; Tsutsumi H
J Child Neurol; 2015 Aug; 30(9):1192-5. PubMed ID: 25143481
[TBL] [Abstract][Full Text] [Related]
38. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
39. [Subependymal Giant Cell Astrocytoma with Tuberous Sclerosis Complex(TSC-SEGA)].
Ichikawa T; Niida Y
No Shinkei Geka; 2022 Jan; 50(1):111-121. PubMed ID: 35169091
[TBL] [Abstract][Full Text] [Related]
40. Subependymal giant-cell astrocytoma associated with tuberous sclerosis: case report.
Ergün R; Okten AI; Yaman M; Gezici AR; Taşkin Y
Neurosurg Rev; 1998; 21(2-3):185-8. PubMed ID: 9795959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
